This review examines the growing tension between profit-driven pharmaceutical development and optimal public health outcomes in contemporary medicine. Evidence suggests that financial incentives have frequently led to questionable practices within the pharmaceutical industry, including promotion of marginally effective medications at premium prices, manipulation of clinical trial data, and systemic underinvestment in areas of significant public health need but limited profit potential. The review presents case studies of specific medications that exemplify these issues and analyzes the structural factors that have enabled such practices. We conclude by proposing comprehensive reforms to pharmaceutical development, regulation, and medical paradigms that could better align industry practices with public health needs and patient welfare. Addressing these systemic issues requires both targeted regulatory interventions and a broader reconsideration of how medical care is conceptualized, delivered, and evaluated.